Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

G1 Therapeutics stock is highly volatile, and investors should be wary now as G1 Therapeutics recently failed to achieve a clinical goal.

The post Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble appeared first on InvestorPlace.

More From InvestorPlace

• The #1 AI Investment Might Be This Company You’ve Never Heard Of
• Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
• Legendary Investor Predicts: “Forget A.I. THIS Technology Is the Future”